Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Company

Pfizer Inc. Reports Q2 2023 Revenues, Signals Shift Beyond COVID-19 Products

Fineline Cube Aug 2, 2023

US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the second...

Company Deals

EQRx Inc. to be Acquired by Revolution Medicines in All-Stock Transaction

Fineline Cube Aug 2, 2023

US-based EQRx Inc. (NASDAQ: EQRX) has revealed that a definitive agreement has been signed for...

Company Deals

GSK Partners with Zuellig Pharma for Vaccine Distribution and Cold-Chain Management in Asia-Pacific

Fineline Cube Aug 2, 2023

GlaxoSmithKline (GSK; NYSE: GSK), a leading global vaccine manufacturer, has signed an agreement with Philippines-based...

Company Drug

Luye Pharma’s Parkinson’s Disease Treatment LY03003 Receives NMPA Review Acceptance

Fineline Cube Aug 2, 2023

Luye Pharma Group (HKG: 2186) has announced that the National Medical Products Administration (NMPA) has...

Company Deals

Mabwell Bioscience Secures Licensing Deals for Denosumab Biosimilars in Egypt and Pakistan

Fineline Cube Aug 2, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced separate licensing and commercialization agreements...

Company Deals

GeneMind Biosciences Secures RMB 400 Million in Series C Financing to Expand Gene Testing

Fineline Cube Aug 2, 2023

Shenzhen-based DNA sequencer specialist, GeneMind Biosciences Co., Ltd, has reportedly raised RMB 400 million in...

Company Deals

Guangzhou Wondfo Biotech Partners with Indonesia’s Kimia Farma in IVD Field

Fineline Cube Aug 2, 2023

China-based Guangzhou Wondfo Biotech Co., Ltd (SHE: 300482) has entered into a partnership with Indonesia’s...

Company Deals

InxMed Partners with GeneQuantum Healthcare to Develop Innovative ADCs

Fineline Cube Aug 2, 2023

China-based firm InxMed (Nanjing) Co., Ltd has announced a strategic partnership with compatriot firm GeneQuantum...

Company Deals

Sansure Biotech Partners with Indonesian Firm for Localized Molecular Diagnostic Production

Fineline Cube Aug 2, 2023

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has announced a strategic partnership with...

Company R&D

Sinopharm Partners with Harbin Institute of Technology to Boost Biomedical Industry Innovation

Fineline Cube Aug 2, 2023

China National Pharmaceutical Group Corporation (Sinopharm, HKG: 1099) has announced a strategic partnership with Harbin...

Company Deals

NK Celltech and RongCan Biotech Partner to Advance mRNA NK Cell Therapy and LNP Delivery System

Fineline Cube Aug 2, 2023

Shanghai-based NK Celltech and RongCan Biotech have entered into a partnership agreement to establish a...

Company Drug

Abbisko Therapeutics Initiates Phase II Clinical Trial for Pimicotinib in Tendon Sheath Giant Cell Tumor

Fineline Cube Aug 2, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the dosing of the first...

Company Deals

CASI Pharmaceuticals Enters Assignment Agreement with Mundipharma for Folotyn Commercialization in China

Fineline Cube Aug 2, 2023

US-based CASI Pharmaceuticals Inc., (NASDAQ: CASI) has announced the execution of an assignment agreement with...

Company Drug

Astellas Pharma’s Zolbetuximab BLA Accepted by China’s CDE for Gastric Cancer Treatment

Fineline Cube Aug 2, 2023

Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that the Center for Drug Evaluation (CDE)...

Company Deals

Shanghai Junshi Biosciences Partners with Zein Biotechnology for PCSK9 mAb Commercialization in China

Fineline Cube Aug 2, 2023

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced a partnership with...

Company

MSD’s Q2 2023 Earnings: Keytruda and Gardasil Drive Growth Amid COVID-19 Sales Decline

Fineline Cube Aug 2, 2023

US-based major Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) has released its financial results...

Company

GluBio Pharmaceutical Secures $22 Million in A+ Round Financing to Advance Protein Degradation Drugs

Fineline Cube Aug 1, 2023

GluBio Pharmaceutical Co., Ltd., an emerging player in targeted protein degradation drug development, has announced...

Company Drug

GSK’s Jemperli Receives FDA Approval for First-Line Treatment of Advanced Endometrial Cancer

Fineline Cube Aug 1, 2023

GSK plc (NYSE: GSK), a major UK pharmaceutical company, has announced that the US Food...

Company Drug

Viatris Inc. Secures FDA Nod for Generic Symbicort Equivalent, Breyna

Fineline Cube Aug 1, 2023

US-based Viatris Inc., (NASDAQ: VTRS) has announced that the US Food and Drug Administration (FDA)...

Company Deals

Mindray Bio-Medical Electronics to Acquire Majority Stake in DiaSys Diagnostic Systems

Fineline Cube Aug 1, 2023

Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760), a leading medical device company based in...

Posts pagination

1 … 546 547 548 … 718

Recent updates

  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.